Follow-up in Gynecological Cancer Survivors (EORTC-1514-QLG-GCG)
Research type
Research Study
Full title
Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study
IRAS ID
254270
Contact name
Andrew Nordin
Contact email
Sponsor organisation
European Organisation for Research and Treatment of Cancer
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study is for gynecological cancer patients who have already had their primary treatment. The most common duration of routine follow up for these patients is 5 years. These visits evaluate how well the illness is being controlled as well as providing psychosocial support for the patient.
It has been recognised that Gynecologic cancer patients experience significant levels of distress, often persisting years after completion of treatment. As a result, there is disagreement as to how often these follow up visits should take place. A concern often raised is the psychological impact on patients when frequent tests are performed
The objective of this study is to identify the physical and/or psychosocial problems after treatment for gynecological cancer.
Patients will be invited to complete one set of patient reported questionnaires when attending the hospital at one of their routine follow-up visits.
The questionnaires will assess the patient's quality of life as well as their satisfaction with the follow-up service that they have received.
This study will take place in NHS sites in the UK as part of a wider international study.
The study is sponsored and coordinated by the EORTC (European Organisation for Research and Treatment of Cancer), a non-profit organisation
based in Brussels.REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
18/NW/0727
Date of REC Opinion
16 Oct 2018
REC opinion
Favourable Opinion